Navigation Links
Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2011 Healthcare Conference in Boston.  

The live presentation takes place on Thursday, September 8, 2011 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
2. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
3. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
4. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
5. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
6. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
7. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
9. Neurocrine Biosciences Reports Third Quarter 2010 Results
10. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
11. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... OSAKA, Japan , Aug. 28, 2014 /PRNewswire/ ... completion of the post-marketing commitment and submissions of ... authorities including the United States ... European Medicines Agency (EMA) and the Japanese Ministry ... Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for ...
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite ... graduates, has published a case study highlighting ... Excellence Course . In September and October 2014, Academy ... to Albuquerque , Indianapolis , Salt ... Photo - http://photos.prnewswire.com/prnh/20140828/140814 Leadership ...
(Date:8/28/2014)... Aug. 28, 2014   Edison Nation Medical ... a worldwide search for product ideas to improve ... Promising ideas uncovered through the 6-month search ( ... device manufacturers and healthcare retailers with whom Edison ... of individuals age 65 and older. ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... , THE WOODLANDS, Texas , ... LXRX ), a biopharmaceutical company focused on discovering and ... quarter and year end 2009 financial results on Tuesday, ... management will hold a conference call and webcast to discuss ...
... , BEDFORD, ... a division of Ben Venue Laboratories, Inc., a provider of select ... for Injection to its existing product line.  This product is ... for Injection is indicated to close a hemodynamically significant patent ductus ...
Cached Medicine Technology:Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010 2Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010 3Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP 2Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP 3
(Date:8/28/2014)... 28, 2014 (HealthDay News) -- Arguments between parents may ... indicates. Parents in more than 200 families were ... At the end of each day, mothers and fathers ... with their children. On days when parents reported ... their children were also strained, according to the study ...
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... Idaho (PRWEB) August 28, 2014 Kirklyn Smith, ... on what may be a new world’s record by walking ... desk.At TrekDesk we are constantly amazed by the thousands of ... but some just seem to stand out more than the ... daily 24 hour step count which tallies a range of ...
(Date:8/28/2014)... 28, 2014 (HealthDay News) -- Lack of sleep not only ... them at increased risk for obesity, researchers warn. The ... when they were aged 16 and 21. Nearly one-fifth of ... when they were age 16, and this group was 20 ... those who got more than eight hours of sleep per ...
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
Breaking Medicine News(10 mins):Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3
... to Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., ... IDMI ) today announced that the European ... MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with ... tumor that typically affects children and young adults. ...
... Clinic Proceedings author reviews the consequencesROCHESTER, Minn., March ... hospital before the treating physician recommends discharge, the ... conditions and the need for readmission, according to ... Mayo Clinic Proceedings. Additionally, the article examines the ...
... 9 Nancy Brinker, famed breast cancer activist and ... be the 2009 recipient of the University of Pittsburgh ... recognition of her outstanding achievements promoting health and preventing ... nearly 30 years ago when she promised her dying ...
... Two Japanese scientists will arrive at the University of ... device that promises to deliver more comprehensive and accurate ... cost of current technologies. , In April, Mikio Kubota ... will join the research team at UH,s Biomedical Imaging ...
... Michigan Catholic Conference Vice President for Public Policy ... regarding an executive order to be issued by ... embryonic stem cell research:"President Obama,s executive order regrettably ... scientific therapeutic advancements. There are endless studies ...
... with MEDITECH Magic through Interface from Iatric Systems, ... Corporation , a leading provider of handheld, ... announced that Ottawa Regional Hospital & Healthcare ... its Barcode Point-of-Care (BPOC) provider to improve bedside ...
Cached Medicine News:Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3Health News:Nancy Brinker to receive 2009 Porter Prize 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 2Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 3Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: